Is dronedarone effective for the prevention of recurrent atrial fibrillation?

摘要

This was an analysis of data from two parallel, multicenter, double-blind, randomized controlled trials-EURIDIS and ADONIS-both of which were sponsored by Sanofi-Aventis. EURIDIS was conducted in 12 European countries and ADONIS in Australia, the US, Canada, South Africa, and Argentina. Patients in both trials were aged 21 years or older and had experienced at least one episode of AF in the 3 months before enrollment. Exclusion criteria included clinically significant sinus-node disease, NYHA class III or IV heart failure (HF), permanent AF, persistent bradycardia (<50 beats per minute [bpm]), second-degree or higher atrioventricular block, and torsades de pointes. Patients who were taking class I or III antiarrhythmic drugs were also excluded.